Exclusive License for Unique Technology From Sandia National Laboratories

Eden has the right technology to not only produce the US demand for Mo-99, but the reactor capacity could meet up to the world demand when asked to do so. The Eden facility will also have the ability to produce a variety of activation isotopes for therapeutic uses in nuclear medicine. This includes Lutetium-177, the future primary radioisotope for cancer treatment. Our concept uses a simple, straightforward, and proven technology that is well developed and ready to be applied, with no technical showstoppers or hurdles to overcome. The Eden solution includes highly experienced team members who not only have the desire, but also the experience and expertise to assure successful outcomes

Eden has exclusive rights to the “All-Target Reactor” concept patented by Sandia National Laboratories. The patent inventors are Dr. Ed Parma and Dr. Richard Coats, two of Eden’s founders. The Eden nuclear reactor technology is very simple. Instead of using a large high-flux reactor to irradiate uranium loaded targets, the Eden reactor core is entirely made out of low-enriched uranium (LEU) targets. Every target can be processed to make Mo-99 and no driver fuel is required. This innovative approach allows Eden to produce Mo-99 without creating spent nuclear fuel. By using this method, the reactor is optimized to produce Mo-99. The reactor operates at 2 MW in an open pool, making it relatively easy to operate and inherently safe. At this power level,only a limited number of targets can be processed each week to meet the US demand for Mo-99. The reactor also has a relatively high thermal neutron flux, allowing for activation locations for the production of significant quantities of transmutation isotopes such as Lu-177.

Another unique feature of Eden’s technology is that the nuclear reactor facility and hot cell facility are combined together such that the targets can be processed immediately after irradiation, minimizing the decay losses experienced at other facilities. The modified Cintichem process is used to chemically separate the Mo-99 from the other fission products. The uranium is also removed from the fission products, allowing it to be recycled back into new targets for future use. The waste stream fission products are solidified and, after decay, shipped to a low-level waste repository located only three miles from our site.